目的：探讨视网膜光凝术联合康柏西普对DR患者房水VEGF、基质细胞衍生因子1(SDF-1)的影响。

方法：选取2016-09/2018-09本院DR患者120例，依据随机数字表分为联合组和光凝组，每组60例，光凝组给予视网膜光凝术治疗，联合组给予视网膜光凝术联合康柏西普玻璃体腔注射治疗。比较两组治疗后房水VEGF、SDF-1及BCVA、CMT、并发症。

结果：联合组和光凝组术后1d房水VEGF(151.46±18.52、186.74±20.17pg/mL)、SDF-1(466.72±50.21、534.46±56.24mg/L)明显低于术前，且联合组低于光凝组(P<0.05)。两组术后1、3mo CMT、BCVA值明显低于术前，且联合组低于光凝组(P<0.05)。联合组和光凝组术后并发症发生率无差异(6.7% vs 5.0%，P>0.05)。

结论：视网膜光凝术联合康柏西普可有效降低DR患者房水VEGF、SDF-1，有利于提高患者治疗疗效，且安全性好。

METHODS: Totally 120 patients with DR were selected from September 2016 to September 2018 in our hospital, according to the random number table, they were divided into combined group and photocoagulation group, 60 cases in each group. The photocoagulation group was treated with retinal photocoagulation, and the combined group was treated with retinal photocoagulation combined intravitreal injection of conbercept. The aqueous humor VEGF, SDF-1, CMT, BCVA and complication were compared between the two groups.

RESULTS: The postoperative aqueous humor(151.46±18.52,186.74±20.17pg/mL), SDF-1(466.72±50.21, 534.46±56.24mg/L)in the combined group and photocoagulation group were significantly lower than those in the preoperative, the combined group were lower than the photocoagulation group(P<0.05). The 1 and 3mo postoperative CMT, BCVA in the combined group and photocoagulation group were significantly lower than those in the preoperative, the combined group were lower than the photocoagulation group(P<0.05). There was no significant difference of the complication rate between combined group and photocoagulation group(6.7% vs 5.0%, P>0.05).

CONCLUSION: Retinal photocoagulation combined with conbercept can effectively reduce the aqueous humor VEGF and SDF-1 in patients with DR, which is conducive to improving the therapeutic effect of patients, and it is safety.